Tucks Triple Relief Hemorrhoidal Cream
NDC Package 10157-2126-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Tucks Triple Relief Hemorrhoidal (white petrolatum, glycerin, pramoxine hydrochloride, and phenylephrine hydrochloride) cream is adults:when practical, clean the affected area with mild soap and warm water and rinse thoroughlygently dry by patting or blotting with toilet tissue or a soft cloth before application of this productwhen first opening the tube, remove foil seal. This formulation utilizes a cream delivery system. Marketed by Blistex Inc., this product is identified by NDC 10157-2126 and is authorized under FDA application M015.

Identification & Billing

NDC Package Code
10157-2126-1
Package Description
1 TUBE, WITH APPLICATOR in 1 CARTON / 26 g in 1 TUBE, WITH APPLICATOR
Product Code
10157-2126
11-Digit Billing Format
10157212601
RxNorm Crosswalk
  • RxCUI: 2701523 - glycerin 15 % / phenylephrine hydrochloride 0.25 % / pramoxine hydrochloride 1 % / white petrolatum 16 % Rectal Cream
  • RxCUI: 2701523 - glycerin 150 MG/ML / petrolatum 160 MG/ML / phenylephrine hydrochloride 2.5 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Cream

Clinical Specifications

Proprietary Name
Tucks Triple Relief Hemorrhoidal
Non-Proprietary Name
White Petrolatum, Glycerin, Pramoxine Hydrochloride, And Phenylephrine Hydrochloride
Substance Name
Glycerin; Phenylephrine Hydrochloride; Pramoxine Hydrochloride; White Petrolatum
Dosage Form
Cream - An emulsion, semisolid3 dosage form, usually containing > 20% water and volatiles5 and/or < 50% hydrocarbons, waxes, or polyols as the vehicle. This dosage form is generally for external application to the skin or mucous membranes.
Administration Route
Topical - Administration to a particular spot on the outer surface of the body. The E2B term TRANSMAMMARY is a subset of the term TOPICAL.
Active Ingredient(s)
Pharmacologic Class
Usage Information
Adults:when practical, clean the affected area with mild soap and warm water and rinse thoroughlygently dry by patting or blotting with toilet tissue or a soft cloth before application of this productwhen first opening the tube, remove foil seal. Do not use if foil seal is broken.apply externally or in the lower portion of the anal canal onlyapply externally to the affected area up to 4 times dailyfor application in the lower anal canal, remove cover from dispensing cap. Attach dispensing cap to tube. Lubricate dispensing cap well, then gently insert dispensing cap partially into the anus.thoroughly clean dispensing cap after each use and replace coverchildren under 12 years of age: ask a doctor

Regulatory & Marketing

Labeler Name
Blistex Inc.
Product Type
Human Otc Drug
FDA Application #
M015
Marketing Category
OTC MONOGRAPH DRUG -
Start Marketing Date
01-06-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 10157-2126-1 identifies a specific commercial package of 1 tube, with applicator in 1 carton / 26 g in 1 tube, with applicator of Tucks Triple Relief Hemorrhoidal, a human over the counter drug labeled by Blistex Inc.. This cream is formulated for topical use and contains glycerin; phenylephrine hydrochloride; pramoxine hydrochloride; white petrolatum as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Blistex Inc. on January 06, 2025. The current certification is valid through December 31, 2026.

How is this Blistex Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 10157212601. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
10157-2126-1
11-Digit CMS (5-4-2)
10157-2126-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.